Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event

Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event

This brief report examined the frequency and characteristics of a significant blood-pressure (BP) increase after Pfizer-BioNTech BNT162b2 vaccination among healthcare workers who were advised to measure their BP at home. A total of 797 participants (mean age 48.1 ± 10.8 years, 63% women, 39% smokers...

Bibliografski detalji
Glavni autori:	Nikolaos Syrigos, Anastasios Kollias, Dimitra Grapsa, Eleni Fyta, Konstantinos G. Kyriakoulis, Ioannis Vathiotis, Elias Kotteas, Ekaterini Syrigou
Format:	Članak
Jezik:	English
Izdano:	MDPI AG 2022-05-01
Serija:	Vaccines
Teme:	BNT162b2 vaccine COVID-19 blood pressure hypertension
Online pristup:	https://www.mdpi.com/2076-393X/10/5/745

Slični predmeti

Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
od: Mina Psichogiou, i dr.
Izdano: (2021-09-01)

Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan
od: Toshio Naito, i dr.
Izdano: (2022-01-01)

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
od: Itzchak Levy, i dr.
Izdano: (2022-07-01)

Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response
od: Areti Tychala, i dr.
Izdano: (2021-12-01)

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis
od: Eli Magen, i dr.
Izdano: (2022-07-01)

Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands
od: Lotus Leonie van den Hoogen, i dr.
Izdano: (2022-09-01)

Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases
od: Napaporn Chantasrisawad, i dr.
Izdano: (2022-05-01)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
od: Stilla Bauernfeind, i dr.
Izdano: (2021-09-01)

Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation
od: Eric Yuk Fai Wan, i dr.
Izdano: (2024-09-01)

Pulmonary Embolism after Vaccination with the COVID-19 Vaccine (Pfizer, BNT162b2): A Case Report
od: Eun-Ju Kim, i dr.
Izdano: (2023-06-01)

Polyneuritis Cranialis Associated with BNT162b2 mRNA COVID-19 Vaccine in a Healthy Adolescent
od: Pimchanok Kulsirichawaroj, i dr.
Izdano: (2022-01-01)

Reports of Batch-Dependent Suspected Adverse Events of the BNT162b2 mRNA COVID-19 Vaccine: Comparison of Results from Denmark and Sweden
od: Vibeke Manniche, i dr.
Izdano: (2024-08-01)

The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation
od: Marika Watanabe, i dr.
Izdano: (2022-01-01)

Anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine and associated factors in Japanese hemodialysis patients
od: Keiji Hirai, i dr.
Izdano: (2024-05-01)

Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome
od: Mohammad Altermanini, i dr.
Izdano: (2023-08-01)

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
od: Jolanta Kiewisz, i dr.
Izdano: (2022-04-01)

Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers
od: Niki Vassilaki, i dr.
Izdano: (2021-08-01)

Specific immune responses after BNT162b2 mRNA vaccination and COVID-19 infection
od: Simona Arientová, i dr.
Izdano: (2023-10-01)

Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
od: Suyanee Mansanguan, i dr.
Izdano: (2022-08-01)

Safety and Immunogenicity of a Single Dose of BNT162b2 COVID-19 mRNA Vaccine in a Warfarin-Treated Protein S Deficient Patient: A Case Report and Literature Review
od: Cucunawangsih Cucunawangsih, i dr.
Izdano: (2022-12-01)

Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccineResearch in context
od: Ivan Odak, i dr.
Izdano: (2024-01-01)

Association between Immunoglobulin G Levels and Adverse Effects Following Vaccination with the BNT162b2 Vaccine among Japanese Healthcare Workers
od: Jun Otani, i dr.
Izdano: (2021-10-01)

BNT162b2 COVID-19 Vaccine Safety among Healthcare Workers of a Tertiary Hospital in Italy
od: Flavia Beccia, i dr.
Izdano: (2023-02-01)

Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult
od: Mazin Barry, i dr.
Izdano: (2022-01-01)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
od: Louise Murdoch, i dr.
Izdano: (2023-09-01)

Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals
od: Evangelos Terpos, i dr.
Izdano: (2021-10-01)

Toxicological Assessments of a Pandemic COVID-19 Vaccine—Demonstrating the Suitability of a Platform Approach for mRNA Vaccines
od: Cynthia M. Rohde, i dr.
Izdano: (2023-02-01)

The BNT162b2 mRNA COVID-19 Vaccine Increases the Contractile Sensitivity to Histamine and Parasympathetic Activation in a Human Ex Vivo Model of Severe Eosinophilic Asthma
od: Luigino Calzetta, i dr.
Izdano: (2023-01-01)

Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera
od: Thomas E. Hickey, i dr.
Izdano: (2025-01-01)

Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination
od: Stilla Bauernfeind, i dr.
Izdano: (2022-09-01)

Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination
od: Timothy E. Albertson, i dr.
Izdano: (2024-03-01)

Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE
od: Sushma Kavikondala, i dr.
Izdano: (2024-05-01)

BNT162b2 COVID-19 Vaccination and Its Effect on Blood Pressure
od: Toh Leong Tan, i dr.
Izdano: (2022-12-01)

BNT162b2 mRNA Vaccination Leads to Long-Term Protection from COVID-19 Disease
od: Claudia Rossi, i dr.
Izdano: (2021-10-01)

Effectiveness of BNT162b2 COVID-19 Vaccine in Preventing Severe Symptomatic Infection among Healthcare Workers
od: Efrén Murillo-Zamora, i dr.
Izdano: (2021-07-01)

Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers
od: Juan F. Delgado, i dr.
Izdano: (2022-06-01)

Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose
od: Nesrin Gareayaghi, i dr.
Izdano: (2022-10-01)

Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2
od: Jean-Louis Bayart, i dr.
Izdano: (2021-06-01)

Allergy to PEG (polyethylene glycol) – sensitivity of basophil activation test with COVID-19 mRNA-vaccine BNT162B2
od: Bernadette Eberlein, i dr.
Izdano: (2024-12-01)

Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents
od: Palittiya Sintusek, i dr.
Izdano: (2022-08-01)